参考文献/References:
[1]中国高血压防治指南修订委员会，高血压联盟（中国），中华医学会心血管病学分会中国医师协会高血压专业委员会，等. 中国高血压防治指南(2018年修订版) [J].中国心血管杂志, 2019, 24(1): 24-56.
[2] Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses[J]. BMJ, 2016, 352:i717.
[3] 胡大一,刘力生,余金明,等.中国门诊高血压患者治疗现状登记研究[J].中华心血管病杂志, 2010,38(3):230-238.
[4] Porapakkham Y, Pattaraarchachai J, Aekplakorn W. Prevalence, awareness, treatment and control of hypertension and diabetes mellitus among the elderly: the 2004 National Health Examination Survey Ⅲ, Thailand[J]. Singapore Med J, 2008, 49(11): 868-873.
[5] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. J Am Coll Cardiol,2018,71(19): e127-e248.
[6] Yandrapalli S, Pal S, Nabors C, et al. Drug treatment of hypertension in older patients with diabetes mellitus[J]. Expert Opin Pharmacother,2018,19(7):633-642.
[7] UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38[J]. BMJ,1998,317(7160):703-713.
[8] Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group[J]. Lancet, 1998,351(9118):1755-1762.
[9] Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report [J]. JAMA,2003,289(19): 2560-2572.
[10] 张文博,黄星荷,李静.高血压的流行趋势和治疗进展2019 [J].心血管病学进展, 2019, 40(3):331-337.
[11] Patel A, Macmahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial[J]. Lancet, 2007, 370(9590):829-840.
[12] Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus [J].New Engl J Med,2010,362(17): 1575-1585.
[13] Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal[J]. J Hypertens, 2009,27(5):923-934.
[14] American Diabetes Association.Standards of medical care in diabetes--2013[J]. Diabetes Care, 2013, 36 (Suppl 1):S11-S66.
[15] American Diabetes Association.Cardiovascular disease and risk management: standards of medical care in diabetes-2019 [J]. Diabetes Care, 2019,42(Suppl 1): S103-S123.
[16] Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis[J]. BMJ, 2013, 347:f6008.
[17] 李波,陈韵岱.胰高血糖素样肽1影响动脉粥样硬化的研究进展[J].中国动脉硬化杂志,2017,25(4):427-432.
[18] Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure [J]. Nat Med, 2013, 19(5):567-575.
[19] Aroor AR, Sowers JR, Bender SB, et al. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats[J]. Endocrinology,2013, 154(7): 2501-2513.
[20] Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) [J]. Diabetes Care, 2009, 32(7): 1224-1230.
[21] Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study [J]. Diabetes Care, 2009, 32(1): 84-90.
[22] Joannides CN, Mangiafico SP, Waters MF, et al. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity [J]. Diabetes Obes Metab, 2017, 19(8): 1135-1146.
[23] Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin[J].J Clin Endocrinol Metab, 2012, 97(3):1020-1031.
[24] Scheen AJ. EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk[J]. Rev Med Liege, 2015, 70(11): 583-589.
[25] Zhao D, Liu H, Dong P. Empagliflozin reduces blood pressure and uric acid in patients?with type 2 diabetes mellitus: a systematic review and meta-analysis?[J]. J Hum Hypertens, 2019, 33(4): 327-339.
[26] American Diabetes Association.Cardiovascular disease and risk management:standards of medical care in diabetes-2018[J]. Diabetes Care,?2018, 41(Suppl 1): S86-S104.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(9):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(9):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(9):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(9):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(9):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(9):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(9):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[10]付士辉李玉龙骆雷鸣沈明志田进文邓珏琳.高血压基础研究现状与进展[J].心血管病学进展,2019,(9):1202.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.004]
FU ShihuiLI YulongLUO LeimingSHEN MingzhiTIAN JinwenDENG Juelin.Status and Progress of Basic Researches about Hypertension[J].Advances in Cardiovascular Diseases,2019,(9):1202.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.004]